Search results
Showing 316 to 330 of 490 results for %s
This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.
NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .
Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis.
This quality standard covers the period before, during and after a young person moves from children’s to adults’ services in all settings where transitions from children’s to adults’ health or social care services take place. It covers all young people (aged up to 25) using children’s health and social care services who are due to make the transition to adults’ services. This includes young people with mental health problems, disabilities and long-term, life-limiting or complex needs, rare diseases and those in secure settings or under the care of local authorities. It describes high-quality care in priority areas for improvement.
View quality statements for QS140Show all sections
Sections for QS140
- Quality statements
- Quality statement 1: Planning transition
- Quality statement 2: Coordinated transition plan
- Quality statement 3: Annual meeting
- Quality statement 4: Named worker
- Quality statement 5: Meeting a practitioner in adults' services
- Quality statement 6: Missed initial appointments after transfer to adults' services
- Update information
NICE's past research and projects
Join NICE's people and communities network
Join NICE's people and communities network
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services.
applicable) Full details of the research recommendation are in evidence review S: outpatient rehabilitation after shoulder replacement ....
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)
Evidence-based recommendations on mogamulizumab (Poteligeo) for previously treated mycosis fungoides and Sézary syndrome in adults.
Read NICE's patient and public involvement policy.
Read NICE's patient and public involvement policy.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures.
This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.
Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)
Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.